BackgroundThe new European Society of Cardiology guidelines for hypertrophic
cardiomyopathy (HCM) define the estimation of sudden cardiac death (SCD)
risk as an integral part of clinical management. An implantable cardioverter
defibrillator (ICD) is recommended (class IIa) when the risk is ≥
6%.ObjectivesTo compare the SCD risk stratification according to the 2011 and 2014
recommendations for ICD implantation in patients with HCM.MethodsRetrospective study including 105 patients diagnosed with HCM. The indication
for ICD was assessed using the 2011 and 2014 guidelines. Statistical
analysis was performed using SPSS software version 19.0.0.2®. The
tests performed were bilateral, considering the significance level of 5% (p
< 0.05).ResultsRegarding primary prevention, according to the 2011 ACCF/AHA recommendations,
39.0% of the patients had indication for ICD implantation (level of evidence
IIa). Using the 2014 guidelines, only 12.4% of the patients had an
indication for ICD implantation. Comparing the two risk stratification
models for patients with HCM, we detected a significant reduction in the
number of indications for ICD implantation (p < 0.001). Of the 41
patients classified as IIa according to the 2011 recommendations, 68.3%
received a different classification according to the 2014 guidelines.ConclusionSignificant differences were found when comparing the SCD risk stratification
for ICD implantation in the two guidelines. The current SCD risk score seems
to identify many low-risk patients who are not candidates for ICD
implantation. The use of this new score results in a significant reduction
in the number of ICD implanted.